Similar articles

• US clinicians' perspectives on how mifepristone regulations affect access to medication abortion and early pregnancy loss care in primary care.

  Srinivasulu S, Yavari R, Brubaker L, Riker L, Prine L, Rubin SE. Srinivasulu S, et al. Contraception. 2021 Jul;104(1):92-97. doi: 10.1016/j.contraception.2021.04.017. Epub 2021 Apr 25. Contraception. 2021. PMID: 33910031
• Medication to Manage Abortion and Miscarriage.

  Beaman J, Prifti C, Schwarz EB, Sobota M. Beaman J, et al. J Gen Intern Med. 2020 Aug;35(8):2398-2405. doi: 10.1007/s11606-020-05836-9. Epub 2020 May 14. J Gen Intern Med. 2020. PMID: 32410127 Free PMC article. Review.
• US federal court upholds limits on abortion drug mifepristone.

  Tanne JH. Tanne JH. BMJ. 2023 Aug 21;382:1924. doi: 10.1136/bmj.p1924. BMJ. 2023. PMID: 37604517 No abstract available.
• Streamlining the Use of Mifepristone for Early Pregnancy Loss Across a Large Health Care System Sets the Stage for Rapid Expansion of Medication Abortion Access in a Post-Roe Environment.

  Chaisson N, Schafer KM. Chaisson N, et al. Ann Fam Med. 2023 Sep-Oct;21(5):469. doi: 10.1370/afm.3005. Epub 2023 Apr 26. Ann Fam Med. 2023. PMID: 37100466 Free PMC article. No abstract available.
• Clinical applications of mifepristone.

  Tang OS, Ho PC. Tang OS, et al. Gynecol Endocrinol. 2006 Dec;22(12):655-9. doi: 10.1080/09513590601005946. Gynecol Endocrinol. 2006. PMID: 17162706 Review.